Professional Summary
Education & Certifications
- Medical Education: University of California at Irvine School of Medicine (1994) CA
- Board Certification: American Board of Internal Medicine, Medical Oncology (2015)
- Fellowship: Stanford University Hematology and Oncology Fellowship (2000) CA
-
- Residency: University of Michigan Health System Internal Medicine Residency (1997) MI
- Internship: University of Michigan Health System Internal Medicine Residency (1995) MI
Publications
-
Favorable treatment outcome in non-Hodgkin's lymphoma patients with "poor" mobilization of peripheral blood progenitor cells
Stockerl-Goldstein, K. E., Reddy, S. A., Horning, S. J., Blume, K. G., Chao, N. J., Hu, W. W., … Negrin, R. S. (2000). Favorable treatment outcome in non-Hodgkin's lymphoma patients with "poor" mobilization of peripheral blood progenitor cells. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 6(5), 506–12. -
T cell antigen receptor vaccines for active therapy of T cell malignancies
Reddy, S. A., Okada, C., Wong, C., Bahler, D., & Levy, R. (2001). T cell antigen receptor vaccines for active therapy of T cell malignancies. Presented at the Conference on Basic and Clinical Relevant Biology of Cutaneous T Cell Lymphoma, NEW YORK,NY,NY,NY,NY,NY,NY: NEW YORK ACAD SCIENCES. -
CD30(+) cutaneous lymphoproliferative disorders: The Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma
Liu, H. L., Hoppe, R. T., Kohler, S., Harvell, J. D., Reddy, S., & Kim, Y. H. (2003). CD30(+) cutaneous lymphoproliferative disorders: The Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 49(6), 1049–58. -
-
Molecular rescue of tumour-specific T cell receptor idiotype from T cell lymphomas
Reddy, S. A., & Levy, R. (2004). Molecular rescue of tumour-specific T cell receptor idiotype from T cell lymphomas. BRITISH JOURNAL OF HAEMATOLOGY, 124(5), 626–28. -
Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: Safety and immunogenicity in a phase I clinical study
McCormick, A. A., Reddy, S., Reinl, S. J., Cameron, T. I., Czerwinkski, D. K., Vojdani, F., … Levy, R. (2008). Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: Safety and immunogenicity in a phase I clinical study. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 105(29), 10131–36. -
Indolent primary cutaneous B-cell lymphoma: Experience using systemic rituximab
Morales, A. V., Advani, R., Horwitz, S. M., Riaz, N., Reddy, S., Hoppe, R. T., & Kim, Y. H. (2008). Indolent primary cutaneous B-cell lymphoma: Experience using systemic rituximab. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 59(6), 953–57. -
Prognostic Factors in Primary Cutaneous Anaplastic Large Cell Lymphoma Characterization of Clinical Subset With Worse Outcome
Woo, D. K., Jones, C. R., Vanoli-Storz, M. N., Kohler, S., Reddy, S., Advani, R., … Kim, Y. H. (2009). Prognostic Factors in Primary Cutaneous Anaplastic Large Cell Lymphoma Characterization of Clinical Subset With Worse Outcome. ARCHIVES OF DERMATOLOGY, 145(6), 667–74. -
A Phase II Study of SGN-30 in Cutaneous Anaplastic Large Cell Lymphoma and Related Lymphoproliferative Disorders
Duvic, M., Reddy, S. A., Pinter-Brown, L., Korman, N. J., Zic, J., Kennedy, D. A., … Kim, Y. H. (2009). A Phase II Study of SGN-30 in Cutaneous Anaplastic Large Cell Lymphoma and Related Lymphoproliferative Disorders. CLINICAL CANCER RESEARCH, 15(19), 6217–6224. -
Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma
Whittaker, S. J., Demierre, M.-F., Kim, E. J., Rook, A. H., Lerner, A., Duvic, M., … Kim, Y. H. (2010). Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma. JOURNAL OF CLINICAL ONCOLOGY, 28(29), 4485–91. -
A Systemic Complete Response of Metastatic Melanoma to Local Radiation and Immunotherapy
Hiniker, S. M., Chen, D. S., Reddy, S., Chang, D. T., Jones, J. C., Mollick, J. A., … Knox, S. J. (2012). A Systemic Complete Response of Metastatic Melanoma to Local Radiation and Immunotherapy. TRANSLATIONAL ONCOLOGY, 5(6), 404–7. -
Markedly improved overall survival in 10 consecutive patients with metastatic basal cell carcinoma.
Danial, C., Lingala, B., Balise, R., Oro, A. E., Reddy, S., Colevas, A., & Chang, A. L. S. (2013). Markedly improved overall survival in 10 consecutive patients with metastatic basal cell carcinoma. British Journal of Dermatology, 169(3), 673–76. -
Markedly improved overall survival in 10 consecutive patients with metastatic basal cell carcinoma
Danial, C., Lingala, B., Balise, R., Oro, A. E., Reddy, S., Colevas, A., & Chang, A. L. S. (2013). Markedly improved overall survival in 10 consecutive patients with metastatic basal cell carcinoma. BRITISH JOURNAL OF DERMATOLOGY, 169(3), 673–76. -
Involution of eruptive melanocytic nevi on combination BRAF and MEK inhibitor therapy.
Chen, F. W., Tseng, D., Reddy, S., Daud, A. I., & Swetter, S. M. (2014). Involution of eruptive melanocytic nevi on combination BRAF and MEK inhibitor therapy. JAMA Dermatology, 150(11), 1209–12. -
Involution of Eruptive Melanocytic Nevi on Combination BRAF and MEK Inhibitor Therapy
Chen, F. W., Tseng, D., Reddy, S., Daud, A. I., & Swetter, S. M. (2014). Involution of Eruptive Melanocytic Nevi on Combination BRAF and MEK Inhibitor Therapy. JAMA DERMATOLOGY, 150(11), 1209–12. -
Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.
Kim, Y. H., Tavallaee, M., Sundram, U., Salva, K. A., Wood, G. S., Li, S., … Horwitz, S. M. (2015). Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project. Journal of Clinical Oncology , 33(32), 3750–58. -
Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma
Kim, E. J., Kim, Y. H., Rook, A. H., Lerner, A., Duvic, M., Reddy, S., … Whittaker, S. (2015). Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma. LEUKEMIA & LYMPHOMA, 56(10), 2847–54. -
Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.
Kim, Y. H., Tavallaee, M., Sundram, U., Salva, K. A., Wood, G. S., Li, S., … Horwitz, S. M. (2015). Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project. Journal of Clinical Oncology , 33(32), 3750–58. -
Tumor DNA in cerebral spinal fluid reflects clinical course in a patient with melanoma leptomeningeal brain metastases
Li, Y., Pan, W., Connolly, I. D., Reddy, S., Nagpal, S., Quake, S., & Gephart, M. H. (2016). Tumor DNA in cerebral spinal fluid reflects clinical course in a patient with melanoma leptomeningeal brain metastases. JOURNAL OF NEURO-ONCOLOGY, 128(1), 93–100. -
A Prospective Clinical Trial Combining Radiation Therapy With Systemic Immunotherapy in Metastatic Melanoma.
Hiniker, S. M., Reddy, S. A., Maecker, H. T., Subrahmanyam, P. B., Rosenberg-Hasson, Y., Swetter, S. M., … Knox, S. J. (2016). A Prospective Clinical Trial Combining Radiation Therapy With Systemic Immunotherapy in Metastatic Melanoma. International Journal of Radiation Oncology, Biology, Physics, 96(3), 578–88. -
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
Nghiem, P. T., Bhatia, S., Lipson, E. J., Kudchadkar, R. R., Miller, N. J., Annamalai, L., … Cheever, M. A. (2016). PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. NEW ENGLAND JOURNAL OF MEDICINE, 374(26), 2542–52. -
Toward rapid learning in cancer treatment selection: An analytical engine for practice-based clinical data.
Finlayson, S. G., Levy, M., Reddy, S., & Rubin, D. L. (2016). Toward rapid learning in cancer treatment selection: An analytical engine for practice-based clinical data. Journal of Biomedical Informatics, 60, 104–13. -
Romidepsin for the treatment of relapsed/refractory cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome): Use in a community setting.
Reddy, S. A. (2016). Romidepsin for the treatment of relapsed/refractory cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome): Use in a community setting. Critical Reviews in Oncology/Hematology, 106, 99–107. -
Phase I Trial: SABR and Ipilimumab-Letter.
Hiniker, S. M., Reddy, S. A., Swetter, S. M., & Knox, S. J. (2017). Phase I Trial: SABR and Ipilimumab-Letter. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 23(1), 320. -
Pembrolizumab for advanced basal cell carcinoma: an investigator-initiated, proof-of-concept study.
Chang, A. L., Tran, D. C., Cannon, J. G., Li, S., Jeng, M., Patel, R., … Colevas, A. D. (2018). Pembrolizumab for advanced basal cell carcinoma: an investigator-initiated, proof-of-concept study. Journal of the American Academy of Dermatology. -
Predicting Response to Immunotherapy by Evaluating Tumors, Lymphoid Cell-Rich Organs, and Immune-Related Adverse Events Using FDG-PET/CT.
Nobashi, T., Baratto, L., Reddy, S. A., Srinivas, S., Toriihara, A., Hatami, N., … Mittra, E. (2019). Predicting Response to Immunotherapy by Evaluating Tumors, Lymphoid Cell-Rich Organs, and Immune-Related Adverse Events Using FDG-PET/CT. Clinical Nuclear Medicine. -
Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy.
Nghiem, P., Bhatia, S., Lipson, E. J., Sharfman, W. H., Kudchadkar, R. R., Brohl, A. S., … Topalian, S. L. (2019). Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO1801896. -
Complete Response of Metastatic Melanoma to Local Radiation and Immunotherapy: 6.5 Year Follow-Up.
Gutkin, P. M., Hiniker, S. M., Swetter, S. M., Reddy, S. A., & Knox, S. J. (2018). Complete Response of Metastatic Melanoma to Local Radiation and Immunotherapy: 6.5 Year Follow-Up. Cureus, 10(12), e3723. -
Management of Immunotherapy-Related Toxicities. Version 1.2019
Thompson, J. A., Schneider, B. J., Brahmer, J., Andrews, S., Armand, P., Bhatia, S., … Scavone, J. L. (2019). Management of Immunotherapy-Related Toxicities. Version 1.2019. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 17(3), 255–88. -
A phase 1b, open-label, investigator-initiated, proof-of-concept study of pembrolizumab for advanced basal cell carcinomas
Chang, A., Duy Tran, Cannon, J., Li, S., Jeng, M., Rieger, K., … Colevas, D. (2019). A phase 1b, open-label, investigator-initiated, proof-of-concept study of pembrolizumab for advanced basal cell carcinomas. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 81(4), AB8. -
Economic analysis of alternative pembrolizumab and nivolumab dosing strategies at an academic cancer center.
Hall, E. T., Zhang, J., Kim, E.-J., Hwang, G., Bhatia, S., & Reddy, S. A. (2019). Economic analysis of alternative pembrolizumab and nivolumab dosing strategies at an academic cancer center. JOURNAL OF CLINICAL ONCOLOGY, 37(15). -
Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced/metastatic melanoma resistant to anti-PD-1/PD-L1 therapy.
Amin, A., Milhem, M. M., Long, G. V., Hoimes, C. J., Medina, T. M., Conry, R. M., … Ribas, A. (2019). Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced/metastatic melanoma resistant to anti-PD-1/PD-L1 therapy. JOURNAL OF CLINICAL ONCOLOGY, 37(15). -
Economics of alternative dosing strategies for pembrolizumab and nivolumab at a single academic cancer center.
Hall, E., Zhang, J., Kim, E. J., Hwang, G., Chu, G., Bhatia, S., & Reddy, S. (2020). Economics of alternative dosing strategies for pembrolizumab and nivolumab at a single academic cancer center. Cancer Medicine. -
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020.
Thompson, J. A., Schneider, B. J., Brahmer, J., Andrews, S., Armand, P., Bhatia, S., … Engh, A. (2020). NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. Journal of the National Comprehensive Cancer Network : JNCCN, 18(3), 230–41. -
A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma.
Postow, M. A., Knox, S. J., Goldman, D. A., Elhanati, Y., Mavinkurve, V., Wong, P., … Barker, C. A. (2020). A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. -
Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy.
Nakamoto, R., Zaba, L. C., Rosenberg, J., Reddy, S. A., Nobashi, T. W., Davidzon, G., … Franc, B. L. (2020). Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy. European Journal of Nuclear Medicine and Molecular Imaging. -
Durability of response in metastatic melanoma patients after combined treatment with radiation therapy and ipilimumab.
Sodji, Q. H., Gutkin, P. M., Swetter, S. M., Reddy, S. A., Hiniker, S. M., & Knox, S. J. (2020). Durability of response in metastatic melanoma patients after combined treatment with radiation therapy and ipilimumab. Melanoma Management, 7(1), MMT36. -
Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial.
Frank, M. J., Khodadoust, M. S., Czerwinski, D. K., Haabeth, O. A., Chu, M. P., Miklos, D. B., … Levy, R. (2020). Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial. The Journal of Experimental Medicine, 217(9). -
Intracranial Tumor Control Following Immune-Related Adverse Events and Discontinuation of Immunotherapy for Melanoma.
Zhang, M., Rodrigues, A. J., Bhambhvani, H. P., Fatemi, P., Pollom, E. L., Gibbs, I. C., … Li, G. (2020). Intracranial Tumor Control Following Immune-Related Adverse Events and Discontinuation of Immunotherapy for Melanoma. World Neurosurgery. -
"Giant cell arteritis manifesting as retinal arterial occlusion and paracentral acute middle maculopathy in a patient on pembrolizumab for metastatic uveal melanoma".
Narala, R., Reddy, S. A., & Mruthyunjaya, P. (2020). "Giant cell arteritis manifesting as retinal arterial occlusion and paracentral acute middle maculopathy in a patient on pembrolizumab for metastatic uveal melanoma". American Journal of Ophthalmology Case Reports, 20, 100891. -
Imaging characteristics and diagnostic performance of F-18-FDG PET/CT for melanoma patients who demonstrate hyperprogressive disease when treated with immunotherapy
Nakamoto, R., Zaba, L., Rosenberg, J., Reddy, S., Nobashi, T., Davidzon, G., … Franc, B. (2020). Imaging characteristics and diagnostic performance of F-18-FDG PET/CT for melanoma patients who demonstrate hyperprogressive disease when treated with immunotherapy. JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC. -
Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy
Nakamoto, R., Zaba, L., Rosenberg, J., Reddy, S., Nobashi, T., Davidzon, G., … Franc, B. (2020). Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy. JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC. -
Immune Profiling and Causal Antigen Discovery in Mouse and Human Models of Immune Checkpoint Inhibitor-induced Myocarditis
Zhu, H., Lee, D., Sarah, W., Galdos, F. X., D'Addabbo, J., Fowler, M. B., … Wu, S. M. (2020). Immune Profiling and Causal Antigen Discovery in Mouse and Human Models of Immune Checkpoint Inhibitor-induced Myocarditis. CIRCULATION RESEARCH. LIPPINCOTT WILLIAMS & WILKINS. -
Prognostic value of bone marrow metabolism on pretreatment 18F-FDG PET/CT in patients with metastatic melanoma treated with anti-PD-1 therapy.
Nakamoto, R., Zaba, L. C., Liang, T., Reddy, S. A., Davidzon, G., Aparici, C. M., … Franc, B. L. (2021). Prognostic value of bone marrow metabolism on pretreatment 18F-FDG PET/CT in patients with metastatic melanoma treated with anti-PD-1 therapy. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. -
Liquid biopsy proteomics of uveal melanoma reveals biomarkers associated with metastatic risk.
Velez, G., Nguyen, H. V., Chemudupati, T., Ludwig, C. A., Toral, M., Reddy, S., … Mahajan, V. B. (2021). Liquid biopsy proteomics of uveal melanoma reveals biomarkers associated with metastatic risk. Molecular Cancer, 20(1), 39. -
Myocarditis Surveillance with High-Sensitivity Troponin I During Cancer Treatment with Immune Checkpoint Inhibitors.
Waliany, S., Neal, J. W., Reddy, S., Wakelee, H., Shah, S. A., Srinivas, S., … Zhu, H. (2021). Myocarditis Surveillance with High-Sensitivity Troponin I During Cancer Treatment with Immune Checkpoint Inhibitors. JACC. CardioOncology, 3(1), 137–39. -
Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma.
Nghiem, P., Bhatia, S., Lipson, E. J., Sharfman, W. H., Kudchadkar, R. R., Brohl, A. S., … Topalian, S. L. (2021). Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma. Journal for Immunotherapy of Cancer, 9(4). -
Complete remission from intralesional talimogene laherparepvec for regionally advanced Merkel cell carcinoma in an immunocompromised solid organ transplant patient.
Hirotsu, K. E., Hua, V., Tran, A. T., Morris, L., Reddy, S. A., Kwong, B. Y., & Zaba, L. C. (2021). Complete remission from intralesional talimogene laherparepvec for regionally advanced Merkel cell carcinoma in an immunocompromised solid organ transplant patient. JAAD Case Reports, 13, 144–146. -
Intracranial Response to Combination BRAF and MEK Inhibitor Therapy in Patients with Metastatic Melanoma
Hui, C., Wu, Y. (F., Liu, K., Sandhu, N., Blomain, E., Binkley, M., … Pollom, E. (2021). Intracranial Response to Combination BRAF and MEK Inhibitor Therapy in Patients with Metastatic Melanoma. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS. LIPPINCOTT WILLIAMS & WILKINS. -
Use of a computer model and care coaches to increase advance care planning conversations for patients with metastatic cancer
Gupta, D., Fardeen, T., Teuteberg, W., Seevaratnam, B., Asuncion, M. K., Alves, N., … Ramchandran, K. (2021). Use of a computer model and care coaches to increase advance care planning conversations for patients with metastatic cancer. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases: Preliminary results of FOCUS (PHP-OCM-301/301A) phase III trial.
Zager, J. S., Orloff, M., Ferrucci, P. F., Glazer, E. S., Ejaz, A., Richtig, E., … Ottensmeier, C. (2021). Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases: Preliminary results of FOCUS (PHP-OCM-301/301A) phase III trial. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
The complexity of carcinosarcoma.
Reddy, S. (1800). The complexity of carcinosarcoma. Oncology (Williston Park, N.Y.), 35(12), 814. -
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology.
Thompson, J. A., Schneider, B. J., Brahmer, J., Achufusi, A., Armand, P., Berkenstock, M. K., … Hang, L. (2022). Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN, 20(4), 387–405. -
Identification of Pathogenic Immune Cell Subsets Associated With Checkpoint Inhibitor-Induced Myocarditis.
Zhu, H., Galdos, F. X., Lee, D., Waliany, S., Vivian Huang, Y., Ryan, J., … Wu, S. M. (2022). Identification of Pathogenic Immune Cell Subsets Associated With Checkpoint Inhibitor-Induced Myocarditis. Circulation, 101161CIRCULATIONAHA121056730. -
Health Care Utilization and Costs in Systemic Therapies for Metastatic Melanoma from 2016 to 2020.
Qian, M. F., Betancourt, N. J., Pineda, A., Maloney, N. J., Nguyen, K. A., Reddy, S. A., … Zaba, L. C. (2022). Health Care Utilization and Costs in Systemic Therapies for Metastatic Melanoma from 2016 to 2020. The Oncologist. -
FOCUS phase 3 trial results: Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases (PHP-OCM-301/301A).
Zager, J. S., Orloff, M. M., Ferrucci, P. F., Glazer, E. S., Ejaz, A., Richtig, E., … Ottensmeier, C. (2022). FOCUS phase 3 trial results: Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases (PHP-OCM-301/301A). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Intracranial Control With Combination BRAF and MEK Inhibitor Therapy in Patients With Metastatic Melanoma.
Hui, C., Wu, Y. F., Liu, K., Sandhu, N., Blomain, E., Binkley, M. S., … Pollom, E. (2022). Intracranial Control With Combination BRAF and MEK Inhibitor Therapy in Patients With Metastatic Melanoma. Cureus, 14(11), e31838. -
ESC Cardio-Oncology Guidelines: A Triumph-But Are We Overscreening?
Witteles, R. M., & Reddy, S. A. (2023). ESC Cardio-Oncology Guidelines: A Triumph-But Are We Overscreening? JACC. CardioOncology, 5(1), 133–136. -
Toward the Development of Functional Biomarker Assays: Analysis of Neoadjuvant Intralesional Oncolytic Virus Response in High-Risk Stage II Melanoma
Kirane, A., Lee, D., Ahmad, M. U., Sharma, S., Serasanambati, M., Lowe, M., … Maverakis, E. (2024). Toward the Development of Functional Biomarker Assays: Analysis of Neoadjuvant Intralesional Oncolytic Virus Response in High-Risk Stage II Melanoma. ANNALS OF SURGICAL ONCOLOGY. SPRINGER. -
Resolution of metastatic neck nodes associated with a periauricular cutaneous squamous cell carcinoma after intranodal injection of talimogene laherparepvec.
Che, Y., Chong, C., Limova, M., Morris, L., Reddy, S. A., & Chang, A. L. (2024). Resolution of metastatic neck nodes associated with a periauricular cutaneous squamous cell carcinoma after intranodal injection of talimogene laherparepvec. JAAD Case Reports, 46, 92–94. -
Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study.
Zager, J. S., Orloff, M., Ferrucci, P. F., Choi, J., Eschelman, D. J., Glazer, E. S., … Ottensmeier, C. H. (2024). Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study. Annals of Surgical Oncology. -
ASO Visual Abstract: Efficacy and Safety of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter, Phase 3 Study.
Zager, J. S., Orloff, M., Ferrucci, P. F., Choi, J., Eschelman, D. J., Glazer, E. S., … Ottensmeier, C. H. (2024). ASO Visual Abstract: Efficacy and Safety of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter, Phase 3 Study. Annals of Surgical Oncology. -
Correction: Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study.
Zager, J. S., Orloff, M., Ferrucci, P. F., Choi, J., Eschelman, D. J., Glazer, E. S., … Ottensmeier, C. H. (2024). Correction: Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study. Annals of Surgical Oncology. -
Circulating Tumor DNA Assay Detects Merkel Cell Carcinoma Recurrence, Disease Progression, and Minimal Residual Disease: Surveillance and Prognostic Implications.
Akaike, T., Thakuria, M., Silk, A. W., Hippe, D. S., Park, S. Y., So, N. A., … Zaba, L. C. (2024). Circulating Tumor DNA Assay Detects Merkel Cell Carcinoma Recurrence, Disease Progression, and Minimal Residual Disease: Surveillance and Prognostic Implications. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2302054. -
Melphalan/hepatic delivery system versus best available care in patients with unresectable metastatic uveal melanoma: Randomized FOCUS trial results
Zager, J. S., Orloff, M. M., Ferrucci, P. F., Choi, J., Eschelman, D. J., Glazer, E. S., … Ottensmeier, C. H. H. (2024). Melphalan/hepatic delivery system versus best available care in patients with unresectable metastatic uveal melanoma: Randomized FOCUS trial results. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
MEK Pathway Inhibitor-Mediated Response in BRAF V600-Mutant Melanoma with Brain Parenchymal and Leptomeningeal Metastases.
Alhusaini, S., Naya, L., Reddy, S. A., & Patel, C. B. (2024). MEK Pathway Inhibitor-Mediated Response in BRAF V600-Mutant Melanoma with Brain Parenchymal and Leptomeningeal Metastases. Annals of Neurology. -
Abscopal Effect in Metastatic Melanoma: Generating Clinical Insights From Radiation-Induced Immune Response.
Nguyen, D. M., Phan, B. N., & Reddy, S. A. (2024). Abscopal Effect in Metastatic Melanoma: Generating Clinical Insights From Radiation-Induced Immune Response. Cureus, 16(11), e72853. -
Management of Immunotherapy-Related Toxicities, Version 2.2024 Featured Updates to the NCCN Guidelines
Thompson, J. A., Schneider, B. J., Brahmer, J., Abu Zaid, M., Achufusi, A., Armand, P., … Hang, L. (2024). Management of Immunotherapy-Related Toxicities, Version 2.2024 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 22(9), 582–592. -
A Novel Intersection: Cytomegalovirus Gastritis Following Cemiplimab and Talimogene Laherparepvec in a Patient With Advanced Cutaneous Squamous Cell Carcinoma.
Egoryan, G., Zimmet, A., Yu, M., Pozdol, J., Subramanian, A., Reddy, S., & Nelson, J. (2024). A Novel Intersection: Cytomegalovirus Gastritis Following Cemiplimab and Talimogene Laherparepvec in a Patient With Advanced Cutaneous Squamous Cell Carcinoma. Clinical Case Reports, 12(12), e9632. -
Clinical Improvement of Treatment-Resistant Metastatic Basal Cell Carcinoma After Intratumoral Injection of Talimogene Laherparepvec.
Che, Y., Abou-Taleb, F., Reddy, S. A., & Chang, A. L. (2025). Clinical Improvement of Treatment-Resistant Metastatic Basal Cell Carcinoma After Intratumoral Injection of Talimogene Laherparepvec. Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]. -
An Open-label, Randomized Study of Melphalan/Hepatic Delivery System Versus Best Alternative Care in Patients with Unresectable Metastatic Uveal Melanoma.
Zager, J. S., Orloff, M., Ferrucci, P. F., Choi, J., Eschelman, D. J., Glazer, E. S., … Ottensmeier, C. H. (2025). An Open-label, Randomized Study of Melphalan/Hepatic Delivery System Versus Best Alternative Care in Patients with Unresectable Metastatic Uveal Melanoma. Annals of Surgical Oncology. -
The association between metformin use, immune mediated colitis and overall survival in patients treated with checkpoint inhibitor.
Shatila, M., Cruz, C. C., Lu, L., Abdul-Baki, K., Baerman, E., Takigawa, K., … Wang, Y. (2025). The association between metformin use, immune mediated colitis and overall survival in patients treated with checkpoint inhibitor. European Journal of Cancer (Oxford, England : 1990), 221, 115405. -
Cardiac Troponin Screening and Clinical Outcomes in Patients Receiving Immunotherapy.
Cheng, E., Ivanovic, M., Chan, A., Xu, S., Franquiz, M., Lee, C., … Zhu, H. (2025). Cardiac Troponin Screening and Clinical Outcomes in Patients Receiving Immunotherapy. JACC. CardioOncology. -
Circulating tumor DNA level is associated with time to clinical recurrence in Merkel cell carcinoma: Implications for patient management.
Akaike, T., Thakuria, M., Silk, A. W., Hippe, D. S., Ch'en, P. Y., Park, S. Y., … Zaba, L. C. (2025). Circulating tumor DNA level is associated with time to clinical recurrence in Merkel cell carcinoma: Implications for patient management. Journal of the American Academy of Dermatology. -
Molecularly Targeted Cancer Medications and Kidney Health.
Ziolkowski, S., Long, J., Zhong, Y., Morgan-Cooper, H., Wakelee, H., Khaki, A., … Anand, S. (2025). Molecularly Targeted Cancer Medications and Kidney Health. JAMA Network Open, 8(11), e2541221. -
Subgroup analyses of the phase 3 FOCUS study of melphalan/hepatic delivery system in patients with unresectable metastatic uveal melanoma.
Zager, J. S., Orloff, M., Ferrucci, P. F., Choi, J., Eschelman, D. J., Glazer, E. S., … Ottensmeier, C. H. (2025). Subgroup analyses of the phase 3 FOCUS study of melphalan/hepatic delivery system in patients with unresectable metastatic uveal melanoma. Journal of Cancer Research and Clinical Oncology, 152(1), 25. -
Metastatic Uveal Melanoma Surveillance: A Delphi Panel Consensus.
Alban, J., Bowen, R. C., Reichstein, D. A., McKean, M., Lutzky, J., Weis, E., … Chandra, S. (2025). Metastatic Uveal Melanoma Surveillance: A Delphi Panel Consensus. Cancers, 18(1). -
Multicenter, randomized, double-blinded, placebo-controlled trial of IFx-Hu2.0 (IFx) as adjunctive therapy with pembrolizumab (pembro) in checkpoint inhibitor (CPI)-naïve patients with advanced or metastatic Merkel cell carcinoma (MCC).
Brohl, A. S., Burgess, M. A., In, G. K., Khaddour, K., O'Neill, P. M., Reddy, S. A., … Bianco, J. A. (2025). Multicenter, randomized, double-blinded, placebo-controlled trial of IFx-Hu2.0 (IFx) as adjunctive therapy with pembrolizumab (pembro) in checkpoint inhibitor (CPI)-naïve patients with advanced or metastatic Merkel cell carcinoma (MCC). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Addressing Biases in Analysis of Time of Infusion: NCI/SWOG Trial S1404 Among Participants With High-Risk Resectable Melanoma Who Received Adjuvant Anti-PD-1 Therapy.
Othus, M., Truong, T.-G. G., Sharon, E., Kendra, K., Grossmann, K., Buchbinder, E., … Patel, S. P. (2026). Addressing Biases in Analysis of Time of Infusion: NCI/SWOG Trial S1404 Among Participants With High-Risk Resectable Melanoma Who Received Adjuvant Anti-PD-1 Therapy. JCO Oncology Practice, OP2501413.
-
Molecular rescue of tumour-specific T cell receptor idiotype from T cell lymphomas
Clinical Trials
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
- Pilot Study of the Safety/Efficacy of Combination Checkpoint Blockade + External Beam Radiotherapy in Stage IV Melanoma
- Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer
- Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma
- Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
- Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma
- Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy
- A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma
- ITIL-168 in Advanced Melanoma
Practice Locations
Skin Cancer Program in Palo Alto Palo Alto, CA
Palo Alto, CA
Skin Cancer Program in Palo Alto
900 Blake Wilbur Dr, 3rd Fl
Palo Alto , CA 94304
Make An Appointment More Clinic Information Getting HereStanford Pigmented Lesion and Melanoma Program at Stanford Cancer Center Palo Alto Palo Alto, CA
Palo Alto, CA
Stanford Pigmented Lesion and Melanoma Program at Stanford Cancer Center Palo Alto
900 Blake Wilbur Dr, 3rd Fl
Palo Alto , CA 94304
Make An Appointment More Clinic Information Getting HereCancer Immunotherapy Program Palo Alto, CA
Palo Alto, CA
Cancer Immunotherapy Program
875 Blake Wilbur Dr
Palo Alto , CA 94304
Make An Appointment More Clinic Information Getting HereOcular and Orbital Oncology Palo Alto, CA
Palo Alto, CA
Ocular and Orbital Oncology
2452 Watson Ct
Palo Alto , CA 94303
Make An Appointment More Clinic Information Getting HereImportant Information about Our Organizations and Physician Affiliation
Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.
Review Summary
Dr. Reddy is known for being caring, personable, and easy to talk to. Patients consistently find him knowledgeable and appreciate his clear communication, particularly his ability to explain complex issues in an understandable way. Many describe him as positive, thorough, and professional.
The summary was created by AI, based on recent patient reviews. Learn more
Was this result useful to you?
Patient Reviews
(216 reviews)
I am alive because of his care.
I have total faith in Dr Reddy as my Oncologist. He will make sure I get the right treatment.
An amazing and excellent doctor in all aspects of his Medical care for me.
Thanks for your professional service
He is a great dr. And explains everything very clearly
I appreciate that Dr. Reddy takes time to review all of my pertinent records.
DR. Reddy is always very positive.
Together with his team and my home team i am alive and thriving ..... Thank you forever and ever and ever!
I brag about Stanford and our great good fortune to receive Care with you all every chance i get!
I only saw Dr. Reddy for a short while. He seemed very competent
Excellent video visit
Doctor; try to be on time, or if late, inform the patient
Excellent clinician
Dr Sunil Reddy is an excellent oncology doctor. He is a caring doctor who knows his field, is open to discussion about one's questions and concerns, consults with doctors in other departments when appropriate, and is a good communicator. I have the highest respect for him and feel fortunate to have him as my doctor.
Many Thanks to Dr. Reddy.
A very caring Doctor. Always has a plan that is easy to understand.
Dr Reddy is an excellent doctor
He is very qualified, of course, but I keep getting conflicting information from the local team and Dr. Reddy.
On time and to the point.
Great communicator. He understands your personal health issues extremely well. Very informative. He is a wealth of information pertaining to my condition. Punctual. Although almost all of the doctors at Stanford are on very tight schedules, Dr Reddy seems to consistantly arrive when scheduled. Caring. Dr Reddy understands the magnitude of the health issues his patients are experiencing and expresses his thoughts, concerns, solutions, and understanding in a very human concerned way.
Dr. Reddy is great, I appreciate him spending time to discuss so much with me.
I'm so grateful that Dr. Reddy is in charge of my care ... he's been able to diagnose and treat my melanoma so that it's now inactive with good prospects in the future. He and his staff are most attentive and always acknowledge me and my concerns. which fortunately, because of their care, I have very few.
Dr. Reddy give plenty of opportunity to voice concerns or issues
He is a top notch professional.
I feel extremely fortunate to be in the receiving end of the care and guidance provided by Dr. Reddy and his team.
I don't have many male doctors but he is one of them. I think of Dr. Reddy as a friend as well as a doctor. He has been excellent as a doctor and I highly recommend him to anyone that needs a good cancer doctor.
Very personable and competent Dr.
It was a great appointment.
Good with providing current information. Explains very well and is concerned about the patient.
He is a very caring and makes me feel confident re my treatment plan
Dr. Reddy is one of the best physicians I've ever had. He is what every medical professional should be. He is kind, considerate, respectful, and most importantly, he listens to me. I don't care if he is running late, because when it's my turn, I never feel rushed.
My experience at Stanford has been as good as it gets. Sure, sometimes it takes longer than it should to get appointments or tests scheduled. But every person on your staff has been very professional, helpful., and kind.
Dr Reddy is easy to talk with. He is very professional but not impersonal. We discussed the treatment for my condition and he suggested that I have a follow up appointment with him after my radiation and scan. I felt that the video visit was well organized from start to finish.
He’s clear in his direction, and always open to questions to ensure understanding.
Excellent and caring!
Dr. Reddy seems to be very knowledgeable and pragmatic. He is very personable.
He is a caring and concerned man.
Dr. Reddy is a kind, considerate and extremely knowledgeable physician.
Excellent oncologist
Dr Reddy is a thorough and clear communicator.
Dr. Reddy is a very skilled and personable Dr. I thank him for allowing an email visit rather than make what is often a two hour or longer trip during rush hour.
DR. Reddy is a very knowledgeable doctor. My wife & I are happy with the treatment he recommends for me.
Dr. Reddy is very caring and easy to talk to.
It was an encouraging visit
I am extremely pleased to have such great attention and care from doctor Reddy and staff everyone is so welcoming and humble to care for your health. The staff are professional and honest and advise you on your personal needs and treatments for the best possible health care.
Dr Reddy is thorough professional and very caring. Sunil’’s expertise is highly appreciated and i recommend him highly.
Thank you for your excellent care.
The Best Stanford Med and Cancer Center have!
Like him as my doctor very much
Dr. Reddy is up front, informative and able to give the information I needed.
Excellent doctor. Compassionate, knowledgeable, communicates well.
Highly recommend.
Thank you for all the support and attention you give to me.
He seems excellent to me.
Really like and appreciate his expertise on my condition. He was 100% there for me and is a true professional. I feel grateful to have Dr. Reddy and his staff supporting me.
Very competent and knowledgeable,. I highly respect his medical judgment.
He’s very knowledgeable and nice
Excellent in every regard
Thorough and clear communicator.
I wrote it in the previous page.
Just adding that all these years that I’ve been seeing Dr Reddy, I’ve been telling my family and friends that I have been lucky to have him as my doctor.
excellent call
Dr. Reddy is positive and helpful. I understand that Merkel Cell is rare and must be treated for at least a year possibly 2 years.
Excellent doctor. I appreciate his wisdom and guidance and gentle manner.
Dr Reddy was easy to understand, and gave good guidance on next steps for my health issues. I appreciate him as a physician that is nice to work with, and makes you feel confident in the health journey.
Outstanding Doctor
I think he is an excellent doctor, he has even taken time to explain to me how cancer works and how radiation works. he has been very good to me as far as I'm concerned. I would gladly recommend him to anyone that I think would need his help.
Very pleasant conversation
He was awesome and very nice and clear with his comments.
Thank you for a good discussion regarding my health concerns and test results.
Very easy to talk with. Very thorough discussion.
He was very helpful
He is a skilled Dr. with a very good reputation.
I have never been disappointed with the medical advice I have gotten at Standard.
He is Excellent. Very Knowledgeable and extremely thorough.
He was very polite and made every effort to be helpful.
Dr. Reddy explains everything very well and I am able to understand them. He answered my questions and gave me the plan forward to treat my cancer.
He is very precise and answered all questions.
Great communicator
Dr. Reddy explains my health issues in layman’s terms which is very helpful. I’m now able to tell my other doctor what we discussed.
Outstanding Physician
Excellent staff and doctor
Excellent doctor! Dr. Reddy is very positive, which is very encouraging for the patient. He is also very knowledgeable and explains things to the patient in a helpful manner.
Informed me of what is going on with my case. Told me how they would proceed, what my options are for treatment & his opininion. Answered my questions and some of my concerns.
Dr Reddy and his staff are very good and a pleasure to work with.
Good video visit -- on time, efficient and through.
Next steps defined.
Brillant physician! He saved my live!
Good communication, answered my questions
Dr. Reddy is very knowledgeable and I feel privileged to have
him involved in my treatment.
Dr. Reddy is one of the most positive and upbeat doctors I’ve met in oncology. He truly wants his patients to be well and to heal. He makes recommendations and suggestions on what to do next. He won’t leave any stone unturned, he digs and digs. I don't have anxiety prior to meeting with Dr Reddy or his team. He treats his staff with dignity and respect when he asks them to do something or to f/u on a test result, etc. He has returned my calls after clinic hours which can be late into the evening, following up on his promise “I’ll call you today†. I am thankful for his dedication and hard Work.
Great
Dr. Reddy is an excellent Doctor and I feel fortunate he has accepted me
as a patient.
He listened well to what I had to say. Told me clearly what steps we would follow going forwards. Arranged for us to connect in the future. Overall, an excellent video call.
Superb doctor! I would recommend him to anyone.
Dr. Sunil Reddy is an outstanding oncologist. He listens to the patient and carefully designs treatments to fit the individual. His treatment for me his so far been successful beyond what I could hope for.
Very clear and direct communicator, and has an excellent bedside manner.
Dr Reddy is easy to understand and is interested in my welfare.
He’s an excellent Dr. and I feel privileged to have him.
Dr. Reddy has a great bedside manner as did Rosa Patel, his associate.
Dr Reddy is a caring person and keeps in touch with others involved with my care, very efficient and pleasant to talk to.
Veryknowledgeable, compassionate physician.
I greatly appreciated his professionalism, clear explanations and forthright recommendations.
He was thoughtful, direct and listened and responded to me as a person ; not just another patient.
I think Dr Reddy is very serious doctor.
I greatly appreciate his expertise and guidance which is always freely given.
Good. Doctor
Amazing
Great doctor, and has done wonderful things in treating by medical issue!
I am grateful for Dr Reddy’s time and knowledge. My appointments with him never feel rushed, I’m provided ample opportunity to ask questions and discuss current happenings. Dr Reddy is always solid on my timeline, don’t have to remind him of anything which makes me feel valued and taken care of. It’s a privilege to have a doctor like Dr Reddy — who knows me, cares about my well-being and whom I can trust without hesitation.
He is an excellent Dr.
He was great, compassionate and just what I needed.
Doctor Reddy is a very nice and helpful doctor.
excellant
Amazing doctor!
Dr. Reddy is a talented, thoughtful, caring physician. I am grateful to be his patient.
It was a well organized vedio visit which I really enjoyed it and fully satisfied. Thank you
I appreciate Dr. Reddy's professionalism, thoughtful communication, and obvious expertise.
Very thorough, caring staff.
Dr. Reddy is an outstanding oncologist. I am so lucky to have had him as my doctor for the last 5 yrs
Dr. Reddy's advice made it possible for me to get all visible signs of cancer out of my body. I plan to continue to rely on his advice.
The best!
Wonderful doctor!! Very thorough, helpful.
Provides excellent care and easy to communicate with
We feel lucky to have Dr. Sunil Reddy as our Oncologist.
Dr Reddy is a top notch, intelligent, kind, personal, communicative dedicated expertise dr!
He is an excellent ‘ compassionate doctor who has given me and my family excellent care over the last 5 years.
He was very thorough and provided a lot of information
Excellent and understandable doctor.
Recommend Stanford to all
good on a video visit.
Thank you and your team for all that you do. People’s life’s are better for the treatments you provide. Let’s hear it for team Reddy. ðŸ‘
They are good, experienced, confidence building individuals.
I am very satisfied with care I have received from Dr.Reddy the past 4 years. I appreciate how he has answered my questions and concerns with compassion and professionalism regarding a worrisome diagnosis.
Dr. Reddy is very connected to the needs and concerns of his patients which makes each visit a positive experience.
Dr. Reddy and his PA offered excellent advice concerning following option after my current surgery.
Dr. Reddy and his team are outstanding!
Dr. Reddy listened & heard my concerns.
Excellent.
Dr. Reddy & his N.P. are very knowledgeable & approachable.
Dr. Reddy & his (PA) (NP) are outstanding when visiting with me.
Feel lucky to have Dr. Reddy as my doctor.
Dr. Reddy is wonderful.
I have recommended this facility and this care provider to many persons.
So far my experience at this facility has been enjoyable, friendly and on time.
Knowledgeable, patient.
Excellent doctor & student doctor.
Dr. Reddy is outstanding - both medically and as a human being.
Dr. Reddy is awesome.
Dr. Reddy and his team are wonderful!
I love Stanford and would recommend it to family and friends.
Dr. Reddy & his whole team are tremendous.
Very positive & informative interaction.
Never received a call back from Dr. Reddy after he reviewed the case. Kaiser indicated he contacted them, but we didn't receive any correspondence from Dr. Reddy & PA.
Entire team is excellent. Check in staff, Dr. Reddy, Dr. Evan Hall, Jaime Reis, NP, Laura Morris, RN.
EVERY question answered w/out feeling rushed.
Sometimes waiting too long. Dr. Reddy kind of quiet, but explained all that was happening.
Good.
Dr. Reddy, Dr. Evan Hall & Laura Morris, RN are phenomenal. They are warm, friendly & caring every single time. Top notch professionals.
Dr. Reddy and his staff are wonderful.
Dr. Reddy and his staff (Laura, Jaime) have always been wonderful and supportive.
Dr. Reddy is a doctor's doctor.
Excellent care team. Great results!
Dr. Reddy is great! Such an excellent care provider.
5. No meds. 6. No follow up.
Was especially impressed where the doctor thanked us for coming 6 hrs. (out of our comfort zone) that he appreciated our confidence in him.
They are very active in the health of the people & also very expert in the care of the patients.
Always recommending my family and friends to Stanford great place and all of you can be very proud of your people you have working for you.
Dr. Reddy is a wonderful doctor.
Incredible doctor and staff!
Dr. Reddy is wonderful!
Good.
Outstanding.
Excellent people.
Dr. Reddy & Laura Morris are AWESOME! #10. Already have.
The whole staff including Dr., nurses & medical staff are all excellent professionals but still very nice & easy to talk with.
We felt Dr. Reddy, and staff knowledgeable respectful, able to teach/explain/answer all our questions. Dr. Reddy and Dr. Swang had a well thought out treatment plan to offer us hope. We left feeling we had gone to the "very best" medical center/doctors, we could have chosen!
Seemed rushed.
Dr. Reddy and Phoung Pham are excellent care providers.
Love my health care staff.
Dr. Sumil Reddy is an incredible doctor. Best ever.
Previously, Dr. Reddy seemed rushed and somewhat dismissive. This time, he was much more attentive and detailed.
Excellent attention.
Dr. Reddy and his staff are excellent!
Great experience with Dr. Reddy, Dr. Mascar, and Jamie Faris.
This was a very good experience a consultation that was not stressful at all.
Thanks for excellent service!
I would highly recommend Dr. Reddy.
Great thank you.
Dr. Reddy is awesome & I feel so blessed to have. He & his staff there for me!
Great doctor.
Dr. Reddy is wonderful - a great care provider.
Extremely pleased.
Dr. Reddy and Laura Morris are beyond fantastic!
Dr. Reddy rocks!!
I have recommended this provider with several people.
I cannot EVEN THINK of a sour note I have only good. I love my time at Stanford!
Excellent.
I have the highest praise for Dr. Reddy. He is personable and friendly, yet very professional. He answers questions well. I have complete confidence in his expertise.
Dr. Reddy was knowledgeable and relayed information in an easily understandable way. He was thorough & presented me with a variety of options. I totally trust his judgment.
I have recommended this care provider several times.
All those extra checks mean I have the best care & the best dr. & nurses - Thank you -
Very thorough, clear & patient w/my questions & concerns.
Dr. Reddy is a great doctor - caring, compassionate, kind and extremely knowledgeable.
Learned a significant amount of information about the medications I am taking.
We are always greeted with a smile and a good word.
I love Dr. Reddy!
The entire team, NP, PA & MD are all the best I could hope for, and I am fortunate to have them.
Dr. Kipp Weis kept was excellent - saw me first. dr. Reddy was outstanding.
I feel he has not informed me well enough as to what's happening, his concerns on explanations. I feel like I'm flying blind!!
I have recommended this provider to several people.
Good.
I have recommended him.
Dr. Reddy has been like a primary care physician. Very good.
Dr. Reddy is outstanding! His care and concern and availability dealing with my stage 4 melanoma problems are a great help.
Dr. Reddy is trying to do everything he can to save my life. I'm so grateful to have him as my dr.
Dr. Reddy is a caring hands on doctor who spends time knowing all issues of my cancer and provides me with excellent personalized service.
Provider seemed perfunctory and no follow-up.
Dr. Reddy and the PA spent an incredible amount of time with me.
Dr. Reddy - excellent doctor.
1 hr. w/me.
Dr. Reddy and David Nguyen spent a TON of time answering all our questions about cancer treatment. Very patient and thorough.
View More Patient Reviews
Referring Physicians
PHYSICIAN HELPLINE
Phone: 1-866-742-4811
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
- Send referrals online
- Place radiology and lab orders
- View referral status
- Access medical records